AU2005216044B2 - Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants - Google Patents

Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants Download PDF

Info

Publication number
AU2005216044B2
AU2005216044B2 AU2005216044A AU2005216044A AU2005216044B2 AU 2005216044 B2 AU2005216044 B2 AU 2005216044B2 AU 2005216044 A AU2005216044 A AU 2005216044A AU 2005216044 A AU2005216044 A AU 2005216044A AU 2005216044 B2 AU2005216044 B2 AU 2005216044B2
Authority
AU
Australia
Prior art keywords
heparin
antithrombin
lung injury
atiii
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005216044A
Other languages
English (en)
Other versions
AU2005216044A1 (en
Inventor
Perenlei Enkhbaatar
Kazunori Murakami
Daniel L. Traber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of AU2005216044A1 publication Critical patent/AU2005216044A1/en
Assigned to BOARD OF REGENTS - THE UNIVERSITY OF TEXAS SYSTEM reassignment BOARD OF REGENTS - THE UNIVERSITY OF TEXAS SYSTEM Amend patent request/document other than specification (104) Assignors: GTC BIOTHERAPEUTICS, INC.
Application granted granted Critical
Publication of AU2005216044B2 publication Critical patent/AU2005216044B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2005216044A 2004-02-20 2005-02-15 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants Ceased AU2005216044B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US54623604P 2004-02-20 2004-02-20
US60/546,236 2004-02-20
US11/057,522 US20050192226A1 (en) 2004-02-20 2005-02-14 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US11/057,522 2005-02-14
PCT/US2005/004604 WO2005081816A2 (en) 2004-02-20 2005-02-15 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011202575A Division AU2011202575A1 (en) 2004-02-20 2011-06-01 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Publications (2)

Publication Number Publication Date
AU2005216044A1 AU2005216044A1 (en) 2005-09-09
AU2005216044B2 true AU2005216044B2 (en) 2011-07-14

Family

ID=34889863

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005216044A Ceased AU2005216044B2 (en) 2004-02-20 2005-02-15 Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Country Status (10)

Country Link
US (2) US20050192226A1 (https=)
EP (2) EP1725244B1 (https=)
JP (2) JP2007533657A (https=)
KR (3) KR20100017971A (https=)
AT (1) ATE493135T1 (https=)
AU (1) AU2005216044B2 (https=)
CA (1) CA2557411A1 (https=)
DE (1) DE602005025610D1 (https=)
IL (1) IL177588A0 (https=)
WO (1) WO2005081816A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20050169908A1 (en) * 2004-01-23 2005-08-04 Kazunori Murakami Use of aerosolized antithrombin to treat acute lung injury
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
US20050245444A1 (en) * 2004-04-30 2005-11-03 Yann Echelard Method of using recombinant human antithrombin for neurocognitive disorders
US20060121004A1 (en) * 2004-12-07 2006-06-08 Yann Echelard Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
KR20140093603A (ko) 2010-12-30 2014-07-28 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 병원체 불활성화제로서의 글리콜
EP2928480B1 (en) 2012-12-05 2019-09-25 National Jewish Health Treatment for airway cast obstruction
US10034921B2 (en) 2013-02-13 2018-07-31 Laboratoire Français Du Fractionnement Et Des Biotechnologies Proteins with modified glycosylation and methods of production thereof
EP3594231A1 (en) 2013-02-13 2020-01-15 Laboratoire Français du Fractionnement et des Biotechnologies Highly galactosylated anti-tnf-alpha antibodies and uses thereof
MX384222B (es) 2013-07-05 2025-03-14 Lab Francais Du Fractionnement Matriz de cromatografia de afinidad.
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
WO2021201950A1 (en) * 2020-04-04 2021-10-07 The Board Of Regents Of The University Of Texas System Method for reducing the occurrence of thrombosis or thromboembolism

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124705A1 (en) * 1995-11-30 2003-07-03 Berry Leslie Roy Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
AU2005208552A1 (en) * 2004-01-23 2005-08-11 Gtc Biotherapeutics, Inc. Use of aerosolized antithrombin to treat acute lung injury

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127347A (en) * 1994-01-12 2000-10-03 Univ Michigan Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
US6355626B1 (en) * 1994-05-13 2002-03-12 The Trustees Of The University Of Pennsylvania Antithrombin agents in treatment of asthma
US5843705A (en) * 1995-02-21 1998-12-01 Genzyme Transgenic Corporation Transgenically produced antithrombin III
US6063593A (en) * 1996-11-12 2000-05-16 University Of Southern California University Park Campus TGFβ1 responsive bone marrow derived cells to express a recombinant protein
US6124257A (en) * 1997-08-28 2000-09-26 Lezdey; John Method of treatment
AU2002224408B2 (en) * 2000-10-18 2007-08-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
DE10132307A1 (de) * 2001-07-06 2003-01-30 Aventis Behring Gmbh Arzneizubereitung zur Inhalation von Antithrombin bei entzündlichen Lungenerkrankungen und ARDS
KR20100117148A (ko) * 2002-04-01 2010-11-02 지티씨바이오쎄라퓨틱스,인크. 폐 질환의 치료 방법
US20050192226A1 (en) * 2004-02-20 2005-09-01 Perenlei Enkhbaatar Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030124705A1 (en) * 1995-11-30 2003-07-03 Berry Leslie Roy Glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
AU2005208552A1 (en) * 2004-01-23 2005-08-11 Gtc Biotherapeutics, Inc. Use of aerosolized antithrombin to treat acute lung injury

Also Published As

Publication number Publication date
KR20100017971A (ko) 2010-02-16
EP1725244A4 (en) 2009-08-12
EP2322189A3 (en) 2011-07-27
EP1725244A2 (en) 2006-11-29
IL177588A0 (en) 2008-03-20
EP1725244B1 (en) 2010-12-29
AU2005216044A1 (en) 2005-09-09
WO2005081816A3 (en) 2007-02-01
EP2322189A2 (en) 2011-05-18
KR20110084555A (ko) 2011-07-25
CA2557411A1 (en) 2005-09-09
JP2011162555A (ja) 2011-08-25
JP2007533657A (ja) 2007-11-22
DE602005025610D1 (de) 2011-02-10
US20110070167A1 (en) 2011-03-24
KR20060130661A (ko) 2006-12-19
US20050192226A1 (en) 2005-09-01
WO2005081816A2 (en) 2005-09-09
ATE493135T1 (de) 2011-01-15

Similar Documents

Publication Publication Date Title
US20110070167A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
Lewis Expanding the clinical indications for α1-antitrypsin therapy
Alam et al. Role of the endogenous elastase inhibitor, elafin, in cardiovascular injury: from epithelium to endothelium
KR101954052B1 (ko) 인공 표면과의 접촉을 포함하는 의료 시술에 투여하기 위한 인자 ｘｉｉ 억제제
US20050169908A1 (en) Use of aerosolized antithrombin to treat acute lung injury
Levi et al. Plasma and plasma components in the management of disseminated intravascular coagulation
CA2879763C (en) The use of antithrombin in extracorporeal membrane oxygenation
US20060121004A1 (en) Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombin
US20050245444A1 (en) Method of using recombinant human antithrombin for neurocognitive disorders
Turner Alpha-1 antitrypsin deficiency: new developments in augmentation and other therapies
US20150071909A1 (en) Methods and compositions for reducing the incidence of post-surgical adhesions
AU2011202575A1 (en) Method of preventing fibrin clots in pulmonary tissue through the use of aerosolized anticoagulants
Luisetti et al. Bioengineering: α1-proteinase inhibitor site-specific mutagenesis: The prospect for improving the inhibitor
KR20040094288A (ko) Ａｒｄｓ의 치료에 있어 변형된 ｆⅶ
US7968515B2 (en) Protein S protects the nervous system from injury
WO2005112968A2 (en) Method of using recombinant human antithrombin for neurocognitive disorders
CN1946419A (zh) 使用气溶胶化抗凝血酶治疗急性肺损伤
P Reeves et al. New strategies in drug development focusing on the anti-protease-protease balance in alpha-1 antitrypsin deficiency
MXPA01005038A (en) Method of treating viral hemorrhagic fever

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired